SILO PHARMA, INC. Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest
SILO PHARMA, INC. (SILO) reported Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest of -$983.25 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Shareholders' Equity
us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest · last filed 2022-11-10
- SILO PHARMA, INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2022-09-30 was -$983.25K, a 115.40% decline year-over-year.
- SILO PHARMA, INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2021-09-30 was $6.39M.
- SILO PHARMA, INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2020-09-30 was -$633.79K.
| Period end | Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 9 month |
|---|---|---|
| 2022-09-30 | -$983.25K 10-Q · filed 2022-11-10 | -$2.25M 10-Q · filed 2022-11-10 |
| 2021-09-30 | $6.39M 10-Q · filed 2022-11-10 | $3.59M 10-Q · filed 2022-11-10 |
| 2020-09-30 | -$633.79K 10-Q · filed 2021-11-10 | -$2.32M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |